A plain language summary of the phase 3 explorer7 study of concizumab prophylaxis for people with hemophilia with inhibitors

This Plain Language Summary of Publication article (PLSP) from Future Rare Diseases, covers the Phase 3 EXPLORER7 study, which evaluated concizumab for boys and men with hemophilia who have inhibitors. Hemophilia is a bleeding disorder where blood does not clot properly, and some patients develop inhibitors that block standard treatments. Concizumab, a new therapy given as a daily injection, was tested as a preventive (prophylactic) treatment and compared to standard on-demand treatment for managing bleeds.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Phase 3 Trial of Concizumab in Hemophilia with Inhibitors’ and was published in the New England Journal of Medicine.

Visit the NEJM using the link to read the original article.

• concizumab
• hemophilia
• plain language summary